LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
Authors:
- C. Faivre-FinnCFC. Faivre-Finn
- D. VicenteDVD. Vicente
- T. KurataTKT. Kurata
- D. PlanchardDPD. Planchard
- L. Paz-AresLPL. Paz-Ares
- J.F. VansteenkisteJVJ.F. Vansteenkiste
- D.R. SpigelDSD.R. Spigel
- M.C. GarassinoMGM.C. Garassino
- M. ReckMRM. Reck
- S. SenanSSS. Senan
- J. NaidooJNJ. Naidoo
- A. RimnerARA. Rimner
- 1 September 2020
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 31, S1178-S1179
Abstract
No abstract availableFunding Information
- AstraZeneca